Citations

Mayo Clinic

Showing 10 of 108599 citations.

Gastrointestinal hospitalization during COVID‐19 pandemic in the United States: Analysis of a nationwide inpatient sample
Wang, Yichen , Huang, Yuting , Zheng, Ting , Yang, Keming , Pang, Maoyin , Pang, Maoyin , Huang, Yuting , Wang, Yichen , Sun, Chenyu

Journal of Gastroenterology and Hepatology | August 15, 2023 | Volume: 38 | Issue: 11 | Pages: 1971-1979

10.1111/jgh.16318 | PMID 37581244 Get It

AbstractBackground and AimWe aim to systematically investigate gastrointestinal (GI) hospitalizations in the United States during the early phase of the COVID‐19 pandemic on a national level and the consequence that may inform practice and policies.MethodsA retrospective cross‐sectional analysis of adult hospitalizations with GI‐related diagnoses or procedures in the United States in 2020 was used, with hospitalizations from 2016 to 2019 used for contextual information.ResultsHospitalizations with principal and secondary GI diagnoses decreased by 13.3% and 8.2% from 2019 to 2020, respectively. Most GI diagnoses decreased in 2020, with a few exceptions including alcoholic liver disease (increased by 7.8% as a principal diagnosis) and acute liver failure (increased by 11.6% as a secondary diagnosis). The mortality rate of hospitalizations with GI disease increased in 2020 compared with 2019 (for principal diagnosis: adjusted odds ratio 1.08, 95% confidence interval 1.03–1.13, P = 0.001; for secondary diagnosis: adjusted odds ratio 1.10, 95% confidence interval 1.07–1.13, P < 0.001). Most GI procedures decreased except for a notable 8.3% increase in gastrostomy. The per‐GI‐hospitalization rate of procedures increased for hospitalizations with a principal GI diagnosis (56.4% vs 55.6%, P = 0.003) or unchanged for hospitalizations with secondary GI diagnoses (18.3% vs 18.2%, P = 0.512).ConclusionThe COVID‐19 pandemic resulted in a decrease in the volume of GI hospitalizations and procedures in 2020, but there was an increase in the mortality rate and some specific diagnoses including alcoholic liver disease and acute liver failure. These findings will likely enlighten future research and healthcare resource allocation for GI diseases.
Abstract B026: Combined inhibition of mammalian target of rapamycin (mTOR) and survivin augments radiation therapy in renal cell carcinoma
Rachamala, Hari K., Dutta, Shamit K., Wang, Enfeng , Rachamalla, Hari Krishnareddy , Rachamala, Hari Krishnareddy , Pal, Krishnendu , Madamsetty, Vijay Sagar , Mukhopadhyay, Debabrata

Cancer Research | August 15, 2023 | Volume: 83 | Issue: 16_Supplement | Pages: B026-B026

10.1158/1538-7445.kidney23-b026 Get It

Abstract Purpose: Although renal cell carcinoma (RCC) is relatively more resistant to radiation therapy (RT) compared to other cancer indications, recent advances in single-fraction and multi-fraction stereotactic ablative radiotherapy (SABR) made it possible to achieve better outcome and reduce treatment related toxicities. In addition, with studies demonstrating that certain therapeutic agents including chemotherapies can act as radiosensitizers, the idea of combining radiotherapy with those agents are being actively pursued. Among them, mammalian target of rapamycin (mTOR) inhibitor everolimus (E) and survivin inhibitor YM155 (Y) are of special interest since they target multiple RT-resistance mechanisms simultaneously. Additionally, YM155 has been shown to help in overcoming resistance to mTOR inhibitors in various cancer including RCC. Hence, the present study aims to evaluate the efficacy of a tumor-targeted liposomal formulation combining everolimus and YM155 (EY-L) in sensitizing RCC tumors towards radiation. Experimental Design: Previously we developed a tumor-targeted liposomal formulation and used it successfully to deliver multiple drugs for the treatment of RCC in both immune-deficient and immune-competent mouse models. Here we developed a similar formulation combining everolimus and YM155 (EY-L) and assessed its efficacy in RCC cell lines in vitro and in RCC tumors in vivo. We further evaluated the efficacy of EY-L in sensitizing RCC cell lines and tumors towards radiation in vitro using clonogenic assay and in vivo in RCC xenografts in immunodeficient mice and murine RCC models in immunocompetent mice. Results: EY-L (2 mg/kg E, 1.4 mg/kg Y, twice a week intravenous administration) was better than E-L or Y-L, the corresponding single drug loaded formulations in containing the primary tumor growth and improving survival in an immunocompetent syngeneic mouse model of RCC. Furthermore, EY-L leads to significantly higher sensitization of RCC cells towards radiation in vitro than E-L or Y-L. Finally, EY-L was able to sensitize RCC tumors towards radiation therapy in both RCC xenograft and murine RCC model. Conclusion: Taken together, our study demonstrated the efficacy of a strategic combination therapy in sensitizing RCC to radiation therapy using in vitro clonogenic assay and in vivo radiosensitization studies in multiple RCC tumor models. Citation Format: Krishnendu Pal, Vijay S. Madamsetty, Hari K. Rachamala, Shamit K. Dutta, Enfeng Wang, Debabrata Mukhopadhyay. Combined inhibition of mammalian target of rapamycin (mTOR) and survivin augments radiation therapy in renal cell carcinoma [abstract]. In: Proceedings of the AACR Special Conference: Advances in Kidney Cancer Research; 2023 Jun 24-27; Austin, Texas. Philadelphia (PA): AACR; Cancer Res 2023;83(16 Suppl):Abstract nr B026.
Cannabis Use in IBD Is Associated With Increased Healthcare Utilization but not With Surgery or Death
Loeb, Lauren , Kinnucan, Jami

Inflammatory Bowel Diseases | August 15, 2023 | Volume: 30 | Issue: 7 | Pages: 1215-1217

10.1093/ibd/izad164 | PMID 37580879 Get It

Planetary Relationships to Birth (Imputed Conception) Rates in Humans: A Signature of Cosmic Origin?
Georgiopoulou, E., Hofmann, S. , Maroudas, Marios , Mastronikolis, Andreas , Matteson, Eric L. , Tsagri, M., Zioutas, K. , Maroudas, Marios , Hofmann, S.

Biophysical Reviews and Letters | August 15, 2023 | Volume: 18 | Issue: 02 | Pages: 107-118

10.1142/s1793048023500029 Get It

This report addresses the time dependence of normal biomedical processes. The conception rate in humans shows relationships that strikingly coincide with planetary periodicities like the orbital period of Jupiter, the 11 years solar cycle and the 237 days Jupiter–Venus synod, and the combined dependence on Jupiter with Mars’ orbital position. The birth rates are used as conception surrogates based on a data set available from the Minnesota Department of Health. The statistical significance of each independent analysis (far) exceeds 5[Formula: see text]. This result cannot be explained with known science. As with other observations in Physics and Medicine (i.e., melanoma), tentatively the only viable explanation we have is the otherwise invisible streaming matter from the dark Universe we live in. The favored dark matter scenario involves streams or clusters as opposed to an isotropic dark sector. The dark Universe scenario has been the driving idea for this type of work. The high sensitivity of living matter to the tiniest external impact might help identify the nature of the dark matter particles, a major problem in all physics since the 1930s. This work is a model for evaluating other biological processes and mutation rates.
Efficacy of anti‐CD3 monoclonal antibodies in delaying the progression of recent‐onset type 1 diabetes mellitus: A systematic review, meta‐analyses and
Ashraf, Muhammad Talal , Rizvi, Syed Hassan Ahmed, Kashif, Muhammad Arham Bin , Asghar, Muhammad Sohaib , Asghar, Muhammad S , Khan, Muhammad Khuzzaim , Ahmed, Syed Hassan

Diabetes, Obesity and Metabolism | August 15, 2023 | Volume: 25 | Issue: 11 | Pages: 3377-3389

10.1111/dom.15237 | PMID 37580969 Get It

Abstract Aim Type 1 diabetes mellitus is widely recognized as a chronic autoimmune disease characterized by the pathogenic destruction of beta cells, resulting in the loss of endogenous insulin production. Insulin administration remains the primary therapy for symptomatic treatment. Recent studies showed that disease‐modifying agents, such as anti‐CD3 monoclonal antibodies, have shown promising outcomes in improving the management of the disease. In late 2022, teplizumab received approval from the US Food and Drug Administration (FDA) as the first disease‐modifying agent for the treatment of type 1 diabetes. This review aims to evaluate the clinical evidence regarding the efficacy of anti‐CD3 monoclonal antibodies in the prevention and treatment of type 1 diabetes. Methods A comprehensive search of PubMed, Google Scholar, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) was conducted up to December 2022 to identify relevant randomized controlled trials. Meta‐analysis was performed using a random‐effects model, and odds ratios with 95% confidence intervals (CIs) were calculated to quantify the effects. The Cochrane risk of bias tool was employed for quality assessment. Results In total, 11 randomized controlled trials involving 1397 participants (908 participants in the intervention arm, 489 participants in the control arm) were included in this review. The mean age of participants was 15 years, and the mean follow‐up time was 2.04 years. Teplizumab was the most commonly studied intervention. Compared with placebo, anti‐CD3 monoclonal antibody treatment significantly increased the C‐peptide concentration in the area under the curve at shorter timeframes (mean difference = 0.114, 95% CI: 0.069 to 0.159, p = .000). Furthermore, anti‐CD3 monoclonal antibodies significantly reduced the patients' insulin intake across all timeframes (mean difference = −0.123, 95% CI: −0.151 to −0.094, p < .001). However, no significant effect on glycated haemoglobin concentration was observed. Conclusion The findings of this review suggest that anti‐CD3 monoclonal antibody treatment increases endogenous insulin production and improves the lifestyle of patients by reducing insulin dosage. Future studies should consider the limitations, including sample size, heterogeneity and duration of follow‐up, to validate the generalizability of these findings further.
Meeting the needs of the patient with non‐English language preference in the hospital setting
Brumbaugh, Jane E. , Tschida‐Reuter, Daniel J., Barwise, Amelia , Barwise, Amelia K , Brumbaugh, Jane E , Tschida-Reuter, Daniel

Health Services Research | August 14, 2023 | Volume: 58 | Issue: 5 | Pages: 965-969

10.1111/1475-6773.14217 | PMID 37580055 Get It

Teaching Video NeuroImage: Inverted Patellar Reflex Localizes the Site of Spinal Epidural Arteriovenous Fistula
Schipani, Elke , Itoh, Christopher Y. , Klaas, James P. , Pinto, Marcus Vinícius , Schipani Bailey, Elke , Klaas, James P , Pinto, Marcus V , Lanzino, Giuseppe

Neurology | August 14, 2023 | Volume: 101 | Issue: 17 | Pages: No page available

10.1212/wnl.0000000000207753 | PMID 37580167 Get It

Retrospective Evaluation of Neuropathologic Proxies of the Minimal Atrophy Subtype Compared With Corticolimbic Alzheimer Disease Subtypes
Boon, Baayla D.C. , Labuzan, Sydney A. , Peng, Zhongwei , Matchett, Billie J. , Hinkle, Kelly M., Lachner, Christian , Ross, Owen A. , Ertekin‐Taner, Nilüfer , Carter, Rickey E. , Ferman, Tanis J. , Duara, Ranjan , Graff‐Radford, Neill R. , Kouri, Naomi , Duara, Ranjan , Dickson, Dennis W , Murray, Melissa E , Ross, Owen A , Carter, Rickey E , Ferman, Tanis J , Dickson, Dennis W. , Murray, Melissa E.

Neurology | August 14, 2023 | Volume: 101 | Issue: 14 | Pages: No page available

10.1212/wnl.0000000000207685 | PMID 37580158 Get It

Treatment of Ruptured Wide‐Necked Aneurysms using a Microcatheter Injectable Biomaterial
Zhang, Zefu , Albadawi, Hassan , Fowl, Richard J., Mayer, Joseph L. , Chong, Brian W. , Öklü, Rahmi , Oklu, Rahmi

Advanced Materials | August 14, 2023 | Volume: 35 | Issue: 46 | Pages: No page available

10.1002/adma.202305868 | PMID 37579579 Get It

Abstract Ruptured wide‐neck aneurysms (WNAs), especially in a setting of coagulopathy, are associated with significant morbidity and mortality. It is shown that by trapping a sub‐millimeter clinical catheter inside the aneurysm sac using a flow diverter stent (FDS), instant hemostasis can be achieved by filling the aneurysm sac using a novel biomaterial, rescuing catastrophic bleeding in large‐animal models. Multiple formulations of a biomaterial comprising gelatin, nanoclay (NC), and iohexol are developed, optimized, and extensively tested in vitro to select the lead candidate for further testing in vivo in murine, porcine, and canine models of WNAs, including in a subset with aneurysm rupture. The catheter‐injectable and X‐ray visible versions of the gel embolic agent (GEA) with the optimized mechanical properties outperform control groups, including a subset that receive a clinically used liquid embolic (Onyx, Medtronic), with and without aneurysm rupture. A combinatorial approach to ruptured WNAs with GEA and FDS may change the standard of medical practice and save lives.